Navigation Links
Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance
Date:1/28/2010

($269 net of tax ($0.01 per diluted share)) of costs related to litigation resulting from our internal stock option investigation.

(D) The quarter ended December 27, 2008 includes a $19,286 ($0.80 per diluted share) non-cash charge for the impairment of all of the goodwill of our Commercial Lasers and Components segment.

(E) Changes in deferred compensation plan liabilities are included in cost of sales and operating expenses while gains and losses on deferred compensation plan assets are included in other income (expense) net.  Deferred compensation expense (benefit) included in operating results is summarized below:

    
    
    
    
    Deferred compensation expense
     (benefit)                                 Three Months Ended
                                               ------------------
                                     January 2,    October 3,    December 27,
                                        2010          2009           2008
                                        ----          ----           ----
    Cost of sales                        $32           $43          $(174)
    Research & development               132           182           (988)
    Selling, general &
     administrative                    1,114         1,476         (5,784)
                                       -----         -----         ------
    Impact on income (loss)
     from operations                  $1,278        $1,701        $(6,946)
                                      ------        ------        -------
    
    

For the quarters ended January 2, 2010, October 3, 2009 and December 27, 2008, the impact on other income (expense) net from gains or losses on deferred compensation plan assets was income of '/>"/>

SOURCE Coherent, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Coherent, Inc. to Webcast Third Fiscal Quarter 2008 Results
2. Coherent, Inc. Announces Termination of SEC Informal Inquiry
3. Coherent, Inc. to Webcast Fourth Fiscal Quarter 2007 Results
4. Coherent, Inc. Receives Expected Letter from NASDAQ
5. Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Medicago reports positive Phase I results for its avian flu pandemic vaccine
8. Neogen Reports 18% Increase in Net Income
9. EntreMed Reports Receipt of Third Quarter Royalty Payment
10. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 01, 2015 Sistemic Ltd. and ... into a commercial collaboration agreement and signed a ... their technologies and work together towards advancing the ... RoosterBio and Sistemic will collaborate on utilizing microRNA ... more precise and relevant characterization panels for hMSC ...
(Date:6/1/2015)... 2015  Berg, a biopharmaceutical company committed to uncovering ... research from its trials using its cancer drug BPM ... on triple negative breast cancer, at the 51 st ... Oncology (ASCO), May 29 – June 2 in ... is one of the first cancer drugs guided in ...
(Date:6/1/2015)... Research and Markets( http://www.researchandmarkets.com/research/5j2hpk/2015_strategies ) ... "2015 Strategies in the US Point-of-Care/POC Clinical ... This new 373-page report contains ... of the POC clinical chemistry market, including ... trends, competitive landscape, and emerging opportunities for ...
(Date:6/1/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced positive, new, long-term ... of AST-VAC1 in patients with intermediate and high ... Company,s autologous (using cells sourced from the patient) ... most common form of acute leukemia in adults ...
Breaking Biology Technology:Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7
... April 28 PharmAthene, Inc. (NYSE Amex: PIP ... threats, today announced the appointment of Mitchel Sayare , Ph.D. ... members. , , ... Dr. Sayare most recently served as Chairman and Chief Executive Officer ...
... ... and Recognition of Science and Technology), a not-for-profit organization founded by inventor Dean Kamen ... Supplier of the FIRST Robotics Competition (FRC®). , ... (PRWEB) April 28, 2010 -- Haydon Kerk Motion Solutions, ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at ... Tuesday, May 4, 2010 at 10:40 a.m. ET / ... chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview. , ... The presentation will be webcast live through the ...
Cached Biology Technology:PharmAthene Appoints Mitchel Sayare, Ph.D. to the Company's Board of Directors 2PharmAthene Appoints Mitchel Sayare, Ph.D. to the Company's Board of Directors 3Haydon Kerk Motion Solutions Inspires Next Generation of Innovators as Silver Supplier of the FIRST Robotics Competition 2Haydon Kerk Motion Solutions Inspires Next Generation of Innovators as Silver Supplier of the FIRST Robotics Competition 3Haydon Kerk Motion Solutions Inspires Next Generation of Innovators as Silver Supplier of the FIRST Robotics Competition 4Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference 2
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... an ongoing effort to mirror the ability of biological ... scientists from the McGowan Institute for Regenerative Medicine have ... both biological and chemical toxins. They described the findings ... biological principles to create materials that can do many ...
... University of Florida engineering researchers have found they can ... say opens the door to a wave of new technologies ... about the research appears in this week,s advance online edition ... Ben Koopman and Brij Moudgil say they used lasers not ...
... from the Robertson Foundation to create a state-of-the-art Translational ... cell therapy research and treatment programs for children and ... suffered at birth. In making the announcement, Victor J. ... Chief Executive Officer for Duke University Health System, said ...
Cached Biology News:Multifunctional polymer neutralizes both biological and chemical weapons 2Engineers: Weak laser can ignite nanoparticles, with exciting possibilities 2Engineers: Weak laser can ignite nanoparticles, with exciting possibilities 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3